Has Cesar Ochoa Perez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,023 in general payments to Cesar Ochoa Perez, MD across 45 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Cesar Ochoa Perez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Cesar Ochoa Perez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Cesar Ochoa Perez, MD

Hematology & Oncology · Plantation, FLNPI 1063788677

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.8% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.

$2,023in general payments, 2019–2025

Across 45 payments — averaging $44.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$242
Regeneron Healthcare Solutions, Inc.$233
Johnson & Johnson$176
Bristol Myers Squibb$150
E.r. Squibb & Sons, L.L.C.$142
Coherus Oncology, Inc.$140
plus $940 from 12 others

$36,955in research payments, 2019–2025

Across 9 payments — averaging $4106.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$23K
Regeneron$14K

What the payments were for

Food & beverage$1,97798%
Education$462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	6	$242
Regeneron Healthcare Solutions, Inc.	4	$233
Johnson & Johnson	2	$176
Bristol Myers Squibb	1	$150
E.r. Squibb & Sons, L.L.C.	7	$142
Coherus Oncology, Inc.	1	$140
Adaptive Biotechnologies Corporation	2	$136
Blueprint Medicines Corporation	1	$129
Merck	6	$125
Genmab U.S., Inc.	1	$124
Genentech USA, Inc.	3	$120
Novartis	3	$88
AbbVie	2	$65
Bayer	2	$64
Seagen Inc.	1	$36
Janssen Scientific Affairs, LLC	1	$20
AstraZeneca	1	$18
Pfizer	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,023 in reported general payments places this provider in the 40th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024

$84,254

Medicare patients

229

Services billed

1,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LenvimaLenvatinib Mesylate	12	$293,613
Dexamethasone	31	$344
Metoclopramide Hcl	14	$328
Levothyroxine Sodium	12	$72

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Plantation

Harshad AminPlantation$159K
Martin DietrichRockledge$6.2M
Mark SocinskiOrlando$2.4M
Tarek MekhailOrlando$2.2M
Edgardo SantosFort Lauderdale$2M
Daniel LandauOrlando$1.8M
Wassim McHaylehAltamonte Springs$1.5M
Edith PerezJacksonville$1.1M
Steven FeinMiami$1M
Vamsidhar VelchetiJacksonville$966K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →